A Multicenter, open-label, uncontrolled study in patients with cancer cachexia
Latest Information Update: 18 May 2022
At a glance
- Drugs Anamorelin (Primary)
- Indications Cachexia
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 10 May 2022 Planned End Date changed from 1 Aug 2018 to 31 Aug 2018.
- 22 Jan 2021 According to an ONO Pharmaceutical media release, based on the results of ONO-7643-04 and ONO-7643-05 studies, the company has received the manufacturing and marketing approval of Adlumiz (anamorelin hydrochloride) Tablet 50mg (Adlumiz), for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer in Japan.
- 15 Aug 2019 Status changed to completed as per results published in the Cancer.